Publication | Closed Access

First-line thalidomide–dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma

Hematological MalignancyTransplantationMarrow TransplantationStem Cell TransplantationImmunologyHematologyYoung PatientsSymptomatic Multiple MyelomaMedicineCell TransplantationFirst-line Thalidomide–dexamethasone Therapy